Evidence map›Paper›PMID 28719656›Full record

ArticlePloS one2017

Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.

Ippokratis Messaritakis, Eleni Politaki, Athanasios Kotsakis, Eleftheria-Kleio Dermitzaki, Filippos Koinis, Eleni Lagoudaki, Anastasios Koutsopoulos, Galatea Kallergi, John Souglakos, Vassilis Georgoulias

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. ES-SCLC Patients with PD-L1Biomedicines · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Circulating tumor cells: biology and clinical significance.Signal transduction and targeted therapy · 2021
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ippokratis MessaritakisLaboratory of Tumor Cell Biology, Medical School, University of Crete, Heraklion, Greece.
Eleni PolitakiLaboratory of Tumor Cell Biology, Medical School, University of Crete, Heraklion, Greece.
Athanasios KotsakisLaboratory of Tumor Cell Biology, Medical School, University of Crete, Heraklion, Greece.
Eleftheria-Kleio DermitzakiDepartment of Medical Oncology, University General Hospital of Heraklion, Crete, Greece.
Filippos KoinisDepartment of Medical Oncology, University General Hospital of Heraklion, Crete, Greece.
Eleni LagoudakiDepartment of Pathology, University General Hospital of Heraklion, Crete, Greece.
Anastasios KoutsopoulosDepartment of Pathology, University General Hospital of Heraklion, Crete, Greece.
Galatea KallergiLaboratory of Tumor Cell Biology, Medical School, University of Crete, Heraklion, Greece.
John SouglakosLaboratory of Tumor Cell Biology, Medical School, University of Crete, Heraklion, Greece.
Vassilis GeorgouliasLaboratory of Tumor Cell Biology, Medical School, University of Crete, Heraklion, Greece.ORCID http://orcid.org/0000-0003-2218-2522

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate the phenotypic heterogeneity of circulating tumor cells (CTCs) based on the expression of proliferative, apoptotic and Epithelial-to-Mesenchymal Transmission (EMT) markers during front-line treatment in patients with small cell lung cancer (SCLC) and to evaluate their clinical relevance.

methodsCTCs from 108 chemotherapy-naïve patients with SCLC were analyzed by double immunofluorescence staining using anti-Ki67, anti-M30, anti-Vimentin along with anti-CKs antibodies. In 83 patients CTCs were also enumerated using the CellSearch.

resultsSequential samples were available from 76 and 48 patients after one-treatment cycle and on disease progression (PD), respectively, for immunofluorescence and from 50 and 36 patients after one-cycle and on PD, respectively, for CellSearch. At baseline, 60.2% of the patients had detectable CTCs by either method. Both proliferative (CK67+) and non-proliferative (Ki67-), apoptotic (M30+) and non-apoptotic (M30-) as well as EMT (Vim+) CTCs were present in the same patient. Among 22 patients without detectable CTCs by CellSearch, CK+/Ki67+ and CK+/Vim+ CTCs could be detected in 6 (27.3%) and 6 (27.3%) patients, respectively. One-chemotherapy cycle reduced both the incidence of detection (p<0.001) and the absolute number (p<0.001) of CTCs; conversely, on PD both the incidence of detection and the number of CTCs were significantly increased (p = 0.002 and p = 0.04, respectively). Multivariate analysis revealed that the increased number of Vim+ CTCs at baseline and of non-apoptotic CTCs on PD could be emerged as independent prognostic factors associated with decreased OS(p = 0.009 and p = 0.023, respectively).

conclusionsCK+/Ki67+, CK+/M30+ and CK+/Vim+ CTCs represent distinct subpopulations of CTCs in patients with SCLC, can be detected even in the absence of detectable CTCs by CellSearch; CK+/Ki67+ and CK+/Vim+ CTCs are associated with unfavorable clinical outcome.

Indexed as

AdultAgedAged, 80 and overCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansKi-67 AntigenLeukocytes, MononuclearLung NeoplasmsMaleNeoplastic Cells, CirculatingSmall Cell Lung CarcinomaVimentinKi-67 AntigenVimentin

Identifiers

PMID28719656
PMCPMC5515424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.